We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




First of Its Kind Multi-Stage Drug-Coated Balloon Technology to Help Fight GI Stenosis

By HospiMedica International staff writers
Posted on 09 Jun 2023

For decades, the approach to treating gastrointestinal (GI) strictures has remained largely unchanged. More...

Now, an innovative technology offers a potential breakthrough in treating individuals with challenging GI strictures, leading to simpler, more cost-effective, and less invasive patient care.

GIE Medical (Brooklyn Park, MN, USA) has developed ProTractX3 TTS DCB for the dilation of recurring benign esophageal strictures in adult patients. These strictures, linked to the narrowing of the esophagus, cause obstructive symptoms in such patients. The ProTractX3 3-Stage TTS DCB is a balloon coated with the chemotherapeutic agent paclitaxel. This drug-coated balloon (DCB), deployable through the scope, presents a novel solution for GI stricture treatment, potentially ensuring long-term sustained patency and reducing the need for multiple treatments.

In December 2022, GIE Medical initiated two extensive, multicenter randomized controlled clinical trials in the United States. These trials are designed to examine the performance of the company's pioneering multi-stage DCB technology, ProTractX3 TTS DCB. The FDA Center for Devices and Radiological Health (CDRH) has awarded GIE Medical the Breakthrough Device Designation to speed up the development of its ProTractX3 TTS DCB. This designation is granted as the device shows significant potential to offer a more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions compared to the existing standard of care.

"We are honored to have our drug-coated balloon catheters selected for the FDA's Breakthrough Device Program for esophageal strictures. This may provide U.S. patients faster access to our novel DCB technology, with the potential to provide safer and more effective treatment," said Lixiao Wang, chairman and CEO of GIE Medical. "This designation will give U.S. gastrointestinal physicians exciting new tools to fight GI stenosis."

Related Links:
GIE Medical


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
12-Channel ECG
CM1200B
New
Dual-Screen Medical Display
C822W
New
Portable Digital Floor Scale
DR400C
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The engine-free, nonlinear, flexible, micro-robotic platform leverages AI to optimize GBM treatment (Photo courtesy of Symphony Robotics)

First-Ever MRI-Steerable Micro-Robotics to Revolutionize Glioblastoma Treatment

Glioblastoma Multiforme (GBM) is one of the most aggressive and difficult-to-treat brain cancers. Traditional surgical procedures, such as craniotomies, involve significant invasiveness, requiring large... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.